Lucid Diagnostics (LUCD) EBITDA Margin (2021 - 2026)
Lucid Diagnostics (LUCD) reported EBITDA Margin of 931.85% for Q1 2026, up 57625.0% on a YoY basis from N/an in Q1 2025, and down 159.77% quarter-over-quarter from 1558.98% in Q4 2025.
Lucid Diagnostics (LUCD) EBITDA Margin (2021 - 2026) Analysis & Trends
Lucid Diagnostics has reported EBITDA Margin for 6 years, with the latest figure at 931.85% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin rose 57625.0% year-over-year to 931.85%; the trailing twelve-month figure through Mar 2026 stood at 226.94% (up 91727.0% YoY), and the FY2025 full-year result was 258.86%, up 80078.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 931.85%, down from 1558.98% in the prior quarter.
- The five-year high for EBITDA Margin was 1558.98% in Q4 2025, with the low at 18917.11% in Q3 2022.
- Historically, EBITDA Margin has averaged 3679.02% across 5 years, with a median of 1123.99% in 2023.
- Annual changes were most pronounced in 2022 — EBITDA Margin sank 1566211 bps — and 2023, when it surged 1749590 bps.
- Lucid Diagnostics' EBITDA Margin stood at 13370.54% in 2022, then surged by 92 bps to 1101.25% in 2023, then rose by 6 bps to 1033.83% in 2024, then soared by 251 bps to 1558.98% in 2025, then plunged by 160 bps to 931.85% in 2026.
- The last three EBITDA Margin figures came in at 931.85% (Q1 2026), 1558.98% (Q4 2025), and 979.92% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 16.24% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 28.97% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 14.52% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 21.42% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 10.04% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 19.94% |
| 10 | Lucid Diagnostics | 149.20 Mn | 121.33 Mn | -325,000.00 | -931.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -931.85% |
| Dec 31, 2025 | 1,558.98% |
| Sep 30, 2025 | -979.92% |
| Jun 30, 2025 | -948.67% |
| Mar 31, 2025 | -1,508.09% |
| Dec 31, 2024 | -1,033.83% |
| Sep 30, 2024 | -997.78% |
| Jun 30, 2024 | -1,146.72% |
| Mar 31, 2024 | -1,078.12% |
| Dec 31, 2023 | -1,101.25% |
| Sep 30, 2023 | -1,421.20% |
| Jun 30, 2023 | -7,285.53% |
| Mar 31, 2023 | -3,210.09% |
| Dec 31, 2022 | -13,370.54% |
| Sep 30, 2022 | -18,917.11% |
| Mar 31, 2022 | -6,492.59% |
| Dec 31, 2021 | -3,747.00% |
| Sep 30, 2021 | -3,255.00% |